Exagen to Announce Second Quarter 2024 Results on August 5, 2024
Exagen(XGN.US) Officer Buys US$77,569.92 in Common Stock
Exagen Inc (XGN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Margin ...
Exagen Is Maintained at Overweight by Cantor Fitzgerald
Exagen Price Target Raised to $7.00/Share From $5.00 by Cantor Fitzgerald
Express News | Cantor Fitzgerald Maintains Overweight on Exagen, Raises Price Target to $7
Exagen Analyst Ratings
Exagen's Strong Q1 Earnings and Growth Potential Justify Buy Rating
Exagen First Quarter 2024 Earnings: Beats Expectations
Buy Rating Affirmed for Exagen Amid Strong Sales Growth and Promising Outlook
Exagen Outperforms: A Strong Buy on Rising Revenues, Margins, and Innovative Growth Prospects
Earnings Call Summary | Exagen(XGN.US) Q1 2024 Earnings Conference
Exagen, Inc. (XGN) Q1 2024 Earnings Call Transcript
Exagen | 10-Q: Quarterly report
Express News | Exagen Increases FY24 Revenue To At Least $55M Vs $54.160M Est
Earnings Flash (XGN) EXAGEN Reports Q1 Revenue $14.4M, Vs. Street Est of $13.1M
Exagen: Existing Cash, Cash Equivalents Adequate to Meet Anticipated Cash Requirements Into 2026 >XGN
Exagen Raises 2024 Guidance >XGN
Express News | Exagen Inc: Sees FY24 Adjusted Ebitda Will Be Better Than Negative $18 Mln
Express News | Exagen Inc: For Full Year 2024 Revenue, Increasing Our Guidance to at Least $55 Mln